Cerus Stock (NASDAQ:CERS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.89

52W Range

$1.38 - $2.59

50D Avg

$1.80

200D Avg

$1.94

Market Cap

$345.43M

Avg Vol (3M)

$1.41M

Beta

1.20

Div Yield

-

CERS Company Profile


Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

625

IPO Date

Jan 31, 1997

Website

CERS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23
Product$156.37M
Government Contract$30.43M

Fiscal year ends in Dec 23 | Currency in USD

CERS Financial Summary


Dec 23Dec 22Dec 21
Revenue$156.40M$162.05M$130.86M
Operating Income$156.40M$-34.08M$-48.94M
Net Income$-37.49M$-42.83M$-54.38M
EBITDA$156.40M$-34.08M$-48.94M
Basic EPS$-0.21$-0.24$-0.32
Diluted EPS$-0.21$-0.24$-0.32

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 11:52 PM
Q2 24Aug 01, 24 | 8:29 PM
Q1 24May 02, 24 | 12:00 AM

Peer Comparison


TickerCompany
CUTRCutera, Inc.
RPIDRapid Micro Biosystems, Inc.
ARAYAccuray Incorporated
BRKRBruker Corporation
OFIXOrthofix Medical Inc.
SGHTSight Sciences, Inc.
ITGRInteger Holdings Corporation
LUNGPulmonx Corporation
NPCENeuroPace, Inc.
SRDXSurmodics, Inc.
MXCTMaxCyte, Inc.
KIDSOrthoPediatrics Corp.
BVSBioventus Inc.
SIBNSI-BONE, Inc.
GKOSGlaukos Corporation
AXGNAxoGen, Inc.
ESTAEstablishment Labs Holdings Inc.
CVRXCVRx, Inc.
CNMDCONMED Corporation